Aura Biosciences to Participate at the 2022 BTIG Biotechnology Conference
August 02 2022 - 7:00AM
Business Wire
Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage
biotechnology company developing a novel class of virus-like drug
conjugate (VDC) therapies for multiple oncology indications, today
announced that Elisabet de los Pinos, PhD, Chief Executive Officer,
and Julie Feder, Chief Financial Officer, of Aura will participate
in a fireside chat at the 2022 Hybrid BTIG Biotechnology Conference
on Monday, August 8, 2022, at 9:00 a.m. ET.
About Aura Biosciences Aura Biosciences, Inc., is a
clinical-stage biotechnology company developing virus-like drug
conjugates (VDCs), a novel class of therapies, for the treatment of
multiple oncology indications. Aura’s lead VDC candidate,
belzupacap sarotalocan (AU-011), consists of a virus-like particle
conjugated with an anti-cancer agent. Belzupacap sarotalocan is
designed to selectively target and destroy cancer cells and
activate the immune system with the potential to create
long-lasting anti-tumor immunity. Belzupacap sarotalocan is
currently in development for ocular cancers, with an ongoing Phase
2 dose escalation clinical trial evaluating it as a first-line
treatment of choroidal melanoma, a vision- and life-threatening
form of eye cancer where standard of care with radiotherapy leaves
patients with severe comorbidities, including major vision loss.
Aura plans to pursue development of belzupacap sarotalocan across
its ocular oncology franchise including for the treatment of
patients with choroidal metastases. In addition, leveraging Aura’s
technology platform, Aura is developing belzupacap sarotalocan more
broadly across multiple cancers, starting with a planned Phase 1
clinical trial in patients with non-muscle invasive bladder cancer
(NMIBC). Aura is headquartered in Boston, MA.
For more information, visit aurabiosciences.com, or follow us on
Twitter and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220802005343/en/
Investor and Media Contact: Matthew DeYoung Argot
Partners 212-600-1902 | aura@argotpartners.com
Aura Biosciences (NASDAQ:AURA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aura Biosciences (NASDAQ:AURA)
Historical Stock Chart
From Apr 2023 to Apr 2024